Home
E-Submission
Sitemap
Contact Us
ABOUT
Aims and scope
About the journal
Editorial board
Best practice
Open access
Contact us
BROWSE ARTICLES
All issues
Current issue
Most read articles
Most download articles
Most cited articles
Search
Author index
EDITORIAL POLICY
Research and publication ethics
Advertising policy
FOR CONTRIBUTORS
Instructions for authors
Author’s checklist
Copyright transfer agreement
Article processing charge
Readership
E-submission
Search
Search
Page Path
HOME
Search
Letter to the Editor
신경면역질환 한글 의학용어 표준화를 위한 예비 조사: 말이집희소돌기아교세포당단백질항체연관질환 용어 선호도
이혜림, 권순욱, 석진명, 김수영, 오성일, 대한신경면역학회 정책위원회
J Mult Scler Neuroimmunol.
2026;17(1):11-13. Published online June 30, 2026
DOI:
https://doi.org/10.59578/jmsni.2026.17.1.11-13
Full text
PubReader
ePub
PDF
Review Article
희귀 신경계질환 극복을 위한 전문가 단체와 환자 단체와의 협력
김기훈, 권영남, 김준순, 김수영, 김승우, 박기홍, 박진성, 봉정빈, 석진명, 석흥열, 이혜림, 조은빈, 전병준, 오성일, 대한신경면역학회 홍보위원회
J Mult Scler Neuroimmunol.
2025;16(1):8-18. Published online June 30, 2025
DOI:
https://doi.org/10.59578/jmsni.2025.16.1.8-18
Cited By 1
Full text
PubReader
ePub
PDF
Case Report
잠복매독 이후 발생한 항 AQP4 항체 음성 시신경척수염스펙 트럼질환 증례
이주헌, 임영기, 김용수, 함주연, 송희정, 이애영, 손은희
J Mult Scler Neuroimmunol.
2016;7(2):59-62. Published online September 1, 2016
PDF
1
Journal of Multiple
Sclerosis and
Neuroimmunology
Print ISSN: 2733-8290
Online ISSN: 2951-2972
MOST VIEWED
MOST CITED
6,065
Autoimmune Nodopathy: When to Suspect and How to Treat?
5,221
National Consensus Guidance for Management of Refractory Myasthenia Gravis
3,911
The Clinical Utility of the Ocrelizumab for the Patients with Multiple Sclerorsis
2,942
Monoclonal Antibody Treatment for Relapse Prevention in Neuromyelitis Optica Spectrum Disorder
2,851
Clinicoradiological Factors for Predicting and Monitoring the Progression of Multiple Sclerosis
+more
Cited By
3
National Consensus Guidance for Management of Refractory Myasthenia Gravis
Cited By
1
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Presenting as a Diffuse Pachymeningitis
Cited By
1
Collaboration between Medical Association and Patient Organizations to Overcome Rare Neurological Disorders
Cited By
1
Ocrelizumab's Place in the Therapeutic Landscape at its 2019 Launch in France
+more